Please assess the completion status of the following clinical trial:

Trial Title: Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older.~* A history typical for recurrent herpes labialis. The subject must have experienced three or more cold sores in the last 12 months.~* In general good health, without other serious medical conditions, as determined by the patient's account of his/her medical history.~* Signature on the informed consent document.~Exclusion Criteria:~* Patients who have participated in an investigational drug study in the four-week period prior to enrollment.~* Previous herpes vaccine at any time.~* Patients with major medical conditions such as chronic heart, pulmonary, renal or hepatic diseases.~* Patients with immunodeficiency disorders such as HIV infection or cancer chemotherapy.~* Patients using topical steroids on or near the face or systemic steroids within 30 days of enrollment.~* Women who are pregnant, lactating or breast feeding.~* Women of childbearing potential not using adequate contraception as judged by the Investigator.~* Recent history of alcohol or drug abuse, which in the opinion of the investigator, may interfere with that study patient's compliance with study requirements.~* Significant skin disease such as atopic dermatitis, acne, or rosacea that would interfere with the assessment of lesions.~* Allergy or hypersensitivity to steroids, acyclovir, penciclovir and/or other nucleoside analogues.~* Subjects with impaired renal function as defined as a serum creatinine above the upper limits of normal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).